Kalvista company profile

Overview

KalVista is a pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors as new treatments for diseases with significant unmet need.

We have developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME).

The strategy is to develop a portfolio of oral molecules and evaluate multiple candidates in the clinic to provide one or more potential best-in-class therapies for HAE and DME patients.

We are developing **KVD900** as an on-demand therapy for acute HAE attacks and reported positive results in a Phase 2 trial. **KVD824** is in development for prophylactic treatment of HAE with a Phase 2 expected to initiate in the second quarter of 2021. Our oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment of HAE for patients. In DME, an intravitreally administered plasma kallikrein inhibitor called **KVD001**, completed a Phase 2 clinical trial in 2019.

We have an R&D team with an established track record in the pharmaceutical development of small molecule protease inhibitors, world-leading expertise in the role of plasma kallikrein in disease, and a management team with the capability to bring small molecules through the clinic to commercialization.

Our offices and labs are in Cambridge, MA and Salisbury, UK.

KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company's HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.

Pipeline

Comments – only KVD900 has an outlook. Others have issues. Results from trials have been delayed frequently.



Employees

60 – comment – more may chiefs (see MT,board) few indians.

Management

Managers

Name	Age	Since	Title
T. Andrew Crockett	45	2016	Chief Executive Officer & Director
Benjamin L. Palleiko	54	2019	Chief Financial & Business Officer
Edward P. Feener, Dr.	60	2016	Chief Scientific Officer
Albert Cha, Dr.	47	2016	Independent Director
Edward W. Unkart	70	2016	Independent Director
Brian Jude Gerard Pereira, Dr.	61	2019	Independent Director
Daniel B. Soland	61	2019	Independent Director
Nancy Stuart	61	2021	Independent Director
Leah Monteiro	-	-	Senior Director-Communications & IR
Andreas Maetzel, Dr.	56	2017	Senior Vice President-Medical

Members of the board

Name	Age	Since	Title
Martin W. Edwards, Dr.	64	2019	Chairman
T. Andrew Crockett	45	2016	Chief Executive Officer & Director
Albert Cha, Dr.	47	2016	Independent Director
Edward W. Unkart	70	2016	Independent Director
Brian Jude Gerard Pereira, Dr.	61	2019	Independent Director
Daniel B. Soland	61	2019	Independent Director
Nancy Stuart	61	2021	Independent Director

Shares

Shareholders

Name	Equities	%
Novo Holdings A/S (Investment Company)	2,725,283	11.2%
SV Health Investors LLC	1,719,576	7.07%
Eventide Asset Management LLC	1,680,000	6.91%
Vivo Capital LLC	1,618,296	6.66%
RA Capital Management LP	1,441,070	5.93%
Merck & Co., Inc.	1,070,589	4.40%
Ikarian Capital LLC	1,063,961	4.38%
Longwood Fund Management LLC	934,484	3.84%
Fidelity Management & Research Co. LLC	904,754	3.72%
Deerfield Management Company LP	890,668	3.66%

Comments:

Kalvista has interest from large institutional investors.

Merck has invested significantly in Kalvista, but also burned their hands after the failure of DME. Merck keeps an eye on them via the board.

Outstanding shares history:

2/28/2017	9.71M
7/1/2017	9.71M
8/31/2017	9.71M
11/30/2017	10.78M
3/1/2018	10.80M
7/16/2018	10.80M
9/10/2018	17.18M
12/10/2018	17.23M
3/10/2019	17.25M
7/1/2019	17.39M
8/30/2019	17.82M
11/30/2019	17.83M
3/2/2020	17.85M
6/24/2020	17.85M
9/4/2020	17.91M
12/3/2020	17.94M
3/4/2021	24.31M

Financials

Comment: Since 2004 (predecessor Carbylan and since start of Kalvista in 2011) negative income.







BRIEF: For the nine months ended 31 January 2021, KalvistaPharmaceuticals Inc revenues decreased from $8.9M to $0K.Net loss increased 39% to $31.3M. Revenues reflect adecrease in demand for the Company's products and servicesdue to unfavorable market conditions. Higher net lossreflects Interest Income decrease of 60% to $589K (income),General and administrative increase of 8% to $10.5M(expense), Other income decrease of 1% to $7.3M (income).

News

KVD824 Phase 2 on Clinical Hold - 20-4-2021

https://www.businesswire.com/news/home/20210420005297/en/KalVista-Pharmaceuticals-Provides-Regulatory-Update-for-Phase-2-Clinical-Trial-of-KVD824

Additional Shares - 16-2-2021

https://www.businesswire.com/news/home/20210216005850/en/KalVista-Pharmaceuticals-Announces-the-Closing-of-its-Upsized-Public-Offering-of-Common-Stock-and-Full-Exercise-of-the-Underwriters%E2%80%99-Option-to-Purchase-Additional-Shares

Nancy Stuart added to Board of Directors - 19-2-2021

https://www.businesswire.com/news/home/20210319005035/en/KalVista-Pharmaceuticals-Appoints-Nancy-Stuart-to-Board-of-Directors

Reports Positive Results for KVD900 Phase 2 9-2-2021

https://www.businesswire.com/news/home/20210209005388/en/KalVista-Pharmaceuticals-Reports-Positive-Results-for-KVD900-Phase-2-Demonstrating-Statistically-and-Clinically-Significant-Responses-Across-All-Endpoints-as-an-Oral-On-Demand-Treatment-for-HAE-Attacks

Provides Update on Oral Hereditary Angioedema Franchise - 15-10-2021

https://www.businesswire.com/news/home/20201015005257/en/KalVista-Pharmaceuticals-Provides-Update-on-Oral-Hereditary-Angioedema-Franchise

KVD900 Phase 2 Trial Recruitment Complete; Data Expected Before End of 2020 –

KVD824 Achieves Targeted Exposure Levels for Prophylaxis; IND Submission Expected Q1 2021 –

KalVista Pharma Eye Drug Partnered With Merck Flunks Phase 2 Test

https://xconomy.com/boston/2019/12/10/kalvista-pharma-eye-drug-partnered-with-merck-flunks-phase-2-test/

Merck pays $760M to buy into KalVista drug for diabetic eye disease

https://www.fiercebiotech.com/biotech/merck-pays-760m-to-buy-into-kalvista-drug-for-diabetic-eye-disease